 |
 |
|
|
|
|
|
Sessions of Interest for the Upcoming 2022 Annual Meeting
|
|
|
|
|
|
| Oral Abstract Session - Kidney and Bladder
|
| 3:45 PM - 6:33 PM |
|
|
|
|
EVEREST: Everolimus for Renal Cancer Ensuing Surgical therapy—A Phase III Study (SWOG S0931, NCT01120249)
Presented By: Christopher W. Ryan, MD
|
|
|
|
|
Association Between Depth of Response (DepOR) and Clinical Outcomes: Exploratory Analysis in Patients with Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 9ER
Presented By: Cristina Suárez, MD
|
|
|
|
|
The Relationship Between Health-Related Quality of Life (HRQoL) and Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma (aRCC) in CheckMate (CM) 214
Presented By: David Cella, FASCO, Ph.D.
|
|
|
|
|
CALYPSO: A Three-Arm Randomized Phase II Study of Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer
Presented By: Thomas Powles, MD, Ph.D., FCRP
|
|
|
|
|
Discussant: Are We Improving Outcomes Comprehensively in Renal Cell Carcinoma?
Presented By: Leonard Appleman, MD, Ph.D.
|
|
|
|
|
Cabozantinib (C) in Combination with Atezolizumab (A) in Urothelial Carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 Study
Presented By: Robert J. Jones, MA, Ph.D., MBChB
|
|
|
|
|
Discussant: Is There a Role for VEGF-TKIs in Bladder Cancer?
Presented By: Shilpa Gupta, MD
|
|
|
|
|
Cell-Free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-Invasive Bladder Cancer in SWOG S1314
Presented By: Yi-Tsung Lu, MD
|
|
|
|
|
TRUCE-02: An Open Label, Single-Arm, Phase II Study of Tislelizumab Combined with Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma
Presented By: HaiTao Wang, MD, MS, Ph.D.
|
|
|
|
|
Final Clinical Results of Pivotal Trial of IL-15RαFc Superagonist N-803 with BCG in BCG-Unresponsive CIS and Papillary Nonmuscle-Invasive Bladder Cancer (NMIBC)
Presented By: Karim Chamie, MD
|
|
|
|
|
Discussant: Are We Improving Outcomes Comprehensively in Renal Cell Carcinoma?
Presented By: Michiel Van Der Heijden, Ph.D., MD
|
|
|
|
|
|
|
|
|
| Best Approaches and Updates for Prostate Cancer Biochemical Recurrence
|
| 4:00 PM - 5:15 PM |
|
|
|
|
Salvage Approaches for Biochemical Recurrence After Radical Prostatectomy
Presented By: Chris C. Parker MD, BA, FRCR
Molecular-Based Imaging Redefining the Disease Landscape
Presented By: Thomas Hope, MD
Reimaging the Timing and Intensity of ADT in Biochemical Recurrence
Presented By: Channing J. Paller, MD
|
|
|
|
|
|
|
|
|
|
Discussant: Moving Beyond TKI and Immuno-oncology in Renal Cell Carcinoma
Presented By: Anil Kapoor, MD
|
|
|
|
|
|
|
|
|
| Oral Abstract Session - Prostate, Testicular, and Penile |
| 9:00 AM - 12:00 AM |
|
|
|
|
TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Progressing After docetaxel—Overall Survival After Median Follow-up of 3 Years (ANZUP 1603)
Presented By: Michael S Hofman FRACP, MBBS
|
|
|
|
|
[177Lu]Lu-PSMA-617 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial
Presented By: Nitin Vaishampayan MD
|
|
|
|
|
[68Ga]Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to [177Lu]Lu-PSMA-617 in Patients with mCRPC: A VISION Substudy
Presented By: Phillip Kuo MD, Ph.D.
|
|
|
|
|
Discussant: Metastatic Castration-Resistant Prostate Cancer: The Future Is Now?
Presented By: Susan F. Slovin MD, Ph.D,. FACP
|
|
|
|
|
Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Ian D. Davis PhD, MBBS, FRACP, FAChPM
A Phase 3 Trial of SHR3680 Versus Bicalutamide in Combination with Androgen Deprivation Therapy (ADT) in Patients with High-Volume Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Ding-Wei Ye
|
|
|
|
|
|
|
|
Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Susan Halabi Ph.D., FASCO
|
|
|
|
|
Discussant: Making Sense of the Intensified mHSPC Landscape
Presented By: Russell Z. Szmulewitz, MD
|
|
|
|
|
Defining Germline Genetics of Germ Cell Tumor: Implications for Genetic Testing and Clinical Management
Presented By: Hong Truong, MD, MS
|
|
|
|
|
Late Relapses in Testicular Cancer: Results from a National Cohort
Presented By: Torgrim Tandstad, MD, Ph.D.
|
|
|
|
|
Discussant: The Natural History and Genetics of Germ Cell Tumors
Presented By: Rahul R. Aggarwal, MD, Ph.D.
|
|
|
|
|
|
|
|
